Replay FDA's July 24 PCAC meeting on emideltide (DSIP), Epitalon, and Semax. The session began at 8 a.m. Eastern and remains available on YouTube.
FDA asked separate questions for the free-base and acetate forms of all three peptides.
Watch the official July 24 PCAC live stream on YouTube.
Results update: Epitalon received a favorable 7–4–1 recommendation, while emideltide received an unfavorable 6–7–1 recommendation. Semax remains pending. Read the complete PCAC Day 2 results.
Watch the July 24 PCAC replay
The official webcast contains the complete second day of the Pharmacy Compounding Advisory Committee meeting. Rebody's PCAC peptide vote tracker lists the verified tallies from both days.
July 24 PCAC agenda
- Emideltide (DSIP): free base and acetate; reviewed for chronic insomnia, narcolepsy, and opioid withdrawal
- Epitalon: free base and acetate; reviewed for insomnia
- Semax: free base and acetate; reviewed for cerebral ischemia, migraine, and trigeminal neuralgia
July 23 results
- BPC-157: two favorable 8–6–1 recommendations
- KPV: favorable committee recommendation
- TB-500: favorable 8–6–1 result
PCAC Day 2 FAQ
Can I still watch the July 24 PCAC meeting?
Yes. FDA's full webcast remains available on YouTube.
Which peptides were on the July 24 PCAC agenda?
Emideltide (DSIP), Epitalon, and Semax.
Where can I see the verified vote totals?
Rebody's PCAC tracker lists the tallies beside the official webcast.